Search

Your search keyword '"Totaro R."' showing total 291 results

Search Constraints

Start Over You searched for: Author "Totaro R." Remove constraint Author: "Totaro R."
291 results on '"Totaro R."'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

2. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

3. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

4. Correction: Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies (Critical Care, (2023), 27, 1, (3), 10.1186/s13054-022-04294-5)

6. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

8. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

9. Signs and symptoms of COVID-19 in patients with multiple sclerosis

11. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

13. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

14. Signs and symptoms of COVID-19 in patients with multiple sclerosis

15. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

16. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

18. The Italian multiple sclerosis register

20. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

21. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

22. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

23. COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ)

24. In-Depth Extracorporeal Cardiopulmonary Resuscitation in Adult Out-of-Hospital Cardiac Arrest

25. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results

26. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

27. COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).

30. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis

32. Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience

38. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

39. Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients

40. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy

41. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study

42. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study

43. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study

44. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis

45. Measurement of d sigma/dy of Drell-Yan e(+)e(-) pairs in the Z mass region from p(p)over-bar collisions at root s=1.96 TeV RID G-1087-2011 RID E-4473-2011

46. Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b

47. Natalizumab Long-Term Treatment Study group. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy

48. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial

49. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial

50. THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS

Catalog

Books, media, physical & digital resources